Literature DB >> 11817656

Signalling pathways in cardiac myocyte hypertrophy.

P H Sugden1.   

Abstract

In response to a requirement for increased contractile power in vivo, mammalian cardiac myocytes adapt through a hypertrophic response (cell enlargement in the absence of cell division). This response can be simulated by exposing isolated myocytes in primary culture to alpha-adrenergic agonists or the vasoactive peptide, endothelin-1. The signalling pathways responsible for hypertrophic growth have been actively studied, and it is likely that reversible protein phosphorylation and dephosphorylation are involved. Three signalling pathways show particular potential as regulators of the response, ie protein kinase C (PKC), mitogen-activated protein kinase (MAPK) cascades, and calcineurin. These species are thought to regulate the rate and specificity of gene transcription ultimately through modifying the transactivating activity of nuclear transcription factors. There are three pertinent MAPK cascades, the extracellular signal-regulated kinase (ERK) cascade, the c-Jun N-terminal kinase (JNK or SAPK1) cascade, and the p38-MAPK (SAPK2-5) cascade. PKC participates in the activation of the ERK cascade but does not contribute significantly to the activation of the two remaining cascades. Calcineurin (or protein phosphatase 2B) is activated by increases in [Ca2+i] through the [Ca2+]-sensing protein, calmodulin. In this review, I discuss the evidence for and against the involvement of these signalling proteins in the induction of myocyte hypertrophy and emphasize that the ERK cascade should perhaps feature more widely in the collective consciousness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817656

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  28 in total

1.  Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.

Authors:  L Tual; O-E Morel; F Favret; M Fouillit; C Guernier; A Buvry; L Germain; G Dhonneur; J-F Bernaudin; J-P Richalet
Journal:  Pflugers Arch       Date:  2006-04-26       Impact factor: 3.657

2.  Matrix elasticity regulates the optimal cardiac myocyte shape for contractility.

Authors:  Megan L McCain; Hongyan Yuan; Francesco S Pasqualini; Patrick H Campbell; Kevin Kit Parker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-28       Impact factor: 4.733

Review 3.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

Review 4.  Compartmentalization of beta-adrenergic signals in cardiomyocytes.

Authors:  Yang K Xiang
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

5.  Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant.

Authors:  Rashmi Choudhary; K P Mishra; C Subramanyam
Journal:  Indian J Clin Biochem       Date:  2006-09

6.  Regulation of cardiac stress signaling by protein kinase d1.

Authors:  Brooke C Harrison; Mi-Sung Kim; Eva van Rooij; Craig F Plato; Philip J Papst; Rick B Vega; John A McAnally; James A Richardson; Rhonda Bassel-Duby; Eric N Olson; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

7.  Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.

Authors:  Koichiro Kinugawa; Mark Y Jeong; Michael R Bristow; Carlin S Long
Journal:  Mol Endocrinol       Date:  2005-04-14

8.  PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.

Authors:  Guey-Shin Wang; Muge N Kuyumcu-Martinez; Satyam Sarma; Nitin Mathur; Xander H T Wehrens; Thomas A Cooper
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

9.  Effect of sodium tanshinone II A sulfonate on phosphorylation of extracellular signal-regulated kinase 1/2 in angiotensin II-induced hypertrophy of myocardial cells.

Authors:  Shu-sheng Li; Jun Feng; Zhi Zheng; Qian-sheng Liang
Journal:  Chin J Integr Med       Date:  2008-08-06       Impact factor: 1.978

10.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.